

TAYSIDE PRESCRIBER

Tayside DTC Supplement No 73

Oct 2007

Produced by NHS Tayside Drug and Therapeutics Committee

SMC Advice issued in October 2007

Medicine	Indication	Local recommendation category	Comments and useful links
Betaine (Cystadane [®])	Homocystinuria	Not recommended	SMC advice
Budesonide rectal foam (Budenofalk [®])	Active ulcerative colitis	Non-formulary	SMC advice SPC link
Ertapenem (Invanz [®])	Prophylaxis of colorectal surgical site infection	Pending antibiotic policy decision	SMC advice
Escitalopram (Ciprallex [®])	Obsessive compulsive disorder	Not recommended	SMC advice
Omalizumab (Xolair [®])	Add-on therapy in severe persistent allergic asthma	Pending development of local protocol	SMC advice
Sitagliptin (Januvia [®])	Type 2 diabetes in combination with metformin	Non-formulary	Alternative to the addition of a glitazone in patients unsuitable for treatment with sulphonylureas Click here for further local advice SMC advice SPC link
Ziconotide (Prialt [®])	Severe, chronic pain in patients who require IT analgesia	Not recommended	SMC advice

Forthcoming SMC Advice

Posaconazole Update - prophylaxis

June 2007 SMC advice for the use of posaconazole for the prophylaxis of invasive fungal infections in immunocompromised patients was deferred to the Antimicrobial Management Group. See below for final decision:

Tayside recommendation

HOSPITAL ONLY (haematology unit)

Use of posaconazole as a prophylactic agent is reserved for the following:

- primary prophylaxis in patients at high risk of invasive fungal infections who are unable to tolerate itraconazole liquid
- secondary prophylaxis in patients who have already had previous treatment for an invasive fungal infection and are at high risk of reactivation

Contact details: Local implementation of SMC recommendations is taken forward by the Tayside Medicines Unit - contact Jan Jones, Principal Pharmacist - Pharmacoeconomics (janjones@nhs.net) if you have any queries in relation to the introduction of new drugs within NHS Tayside.

This bulletin is based on evidence available to the Tayside Medicines Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use and access to the NHS Tayside Drug and Therapeutics Committee website (www.nhstaysideadtc.scot.nhs.uk).